Gude Sai Sravya, Peddi Nikhil Chowdary, Vuppalapati Sravya, Venu Gopal Shravya, Marasandra Ramesh Harshita, Gude Sai Sreeya
Pediatrics, Guntur Medical College, Guntur, IND.
Pediatrics, PES Institute of Medical Sciences and Research, Kuppam, IND.
Cureus. 2022 Mar 16;14(3):e23215. doi: 10.7759/cureus.23215. eCollection 2022 Mar.
Neonatal sepsis is a common cause of neonatal morbidity and mortality. The diagnosis of newborn sepsis is still difficult. Different early objective diagnostic tests or specific signs and symptoms, particularly in preterm infants, make it difficult to diagnose neonatal sepsis. This review article describes biomarkers and their role in the early diagnosis, treatment, and prognosis of neonatal sepsis. It also explores the possible advances and future prospects of these biomarkers. An ideal sepsis biomarker will not only help in the guidance of the use of antibiotics when not needed but also the duration of the course of antibiotics if sepsis is proven. It should also have high sensitivity, specificity, positive predictive value, and negative predictive value. These biomarkers hold a promising position in the management of neonatal sepsis and translate into use in clinical settings. Metabolomics, a diagnostic method based on detecting metabolites found in biological fluids, may open new possibilities in the management of critically ill newborns.
新生儿败血症是新生儿发病和死亡的常见原因。新生儿败血症的诊断仍然困难。不同的早期客观诊断测试或特定的体征和症状，尤其是在早产儿中，使得新生儿败血症难以诊断。这篇综述文章描述了生物标志物及其在新生儿败血症早期诊断、治疗和预后中的作用。它还探讨了这些生物标志物可能的进展和未来前景。理想的败血症生物标志物不仅有助于在不需要时指导抗生素的使用，而且在败血症得到证实时有助于确定抗生素疗程的时长。它还应具有高灵敏度、特异性、阳性预测值和阴性预测值。这些生物标志物在新生儿败血症的管理中具有广阔前景，并可转化应用于临床。代谢组学是一种基于检测生物体液中代谢物的诊断方法，可能为危重新生儿的管理开辟新的可能性。
